



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Demo Report

Report Issued 04/21/2022 18:07
Last Report Issued 02/09/2012 08:04

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 3075SP
Patient ID 3075SP
Chain 12000319
DOB Not Given
Sex Not Given
Workorder 12000319
Received 02/09/2012

Lab ID 12000319-001
Matrix Serum
Patient Name 3075SP
Patient ID 3075SP
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

3075SP Mirtazapine, Serum/Plasma

Analysis by Gas Chromatography (GC)

Mirtazapine	None Detected	ng/mL	5.0	
-------------	---------------	-------	-----	--

Synonym(s): Remeron®

Steady-state peak (0.7 to 4.8 hours post-dose) and trough plasma concentrations following a daily regimen:
15 mg/day: 27 - 51 ng/mL peak; 4.3 - 12 ng/mL trough
30 mg/day: 56 - 104 ng/mL peak; 11 - 25 ng/mL trough
45 mg/day: 84 - 142 ng/mL peak; 17 - 39 ng/mL trough
60 mg/day: 117 - 199 ng/mL peak; 24 - 52 ng/mL trough
75 mg/day: 137 - 225 ng/mL peak; 28 - 64 ng/mL trough

Elimination half-life: 20 to 40 hours.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.